Corcept Therapeutics’ Lifyorli and Impact Therapeutics’ Sepalna are on track for pan-EU marketing approval to treat patients with certain forms of ovarian, fallopian tube, or primary peritoneal cancer.
Corcept Therapeutics’ Lifyorli and Impact Therapeutics’ Sepalna are on track for pan-EU marketing approval to treat patients with certain forms of ovarian, fallopian tube, or primary peritoneal cancer.